News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...